Pinz Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Pinz Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$270K	Buy	+3,400	New	+$287K	0.49%	62
2022 Q1	–	Sell	-7,200	Closed	-$806K	–	225
2021 Q4	$806K	Buy	7,200 +3,800	+112%	+$458K	0.31%	87
2021 Q3	$427K	Buy	+3,400	New	+$438K	0.19%	72
2021 Q2	–	Sell	-3,000	Closed	-$407K	–	574
2021 Q1	$407K	Buy	+3,000	New	+$449K	0.11%	97

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Pinz Capital Management's XBI Position: Q3 2022 in Review

Pinz Capital Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2022: 3,400 shares worth $270K. The stake represents 0.49% of the portfolio and ranks #62 among its holdings. This is a return to the name: Pinz Capital Management previously reported a position in XBI as recently as Q4 2021.

Pinz Capital Management first reported a position in XBI in Q1 2021 and has held it in 4 quarters since. The position peaked at $806K in Q4 2021. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

Pinz Capital Management held 3,400 shares of State Street SPDR S&P Biotech ETF worth $270K as of Q3 2022.
State Street SPDR S&P Biotech ETF was a new Pinz Capital Management position in Q3 2022.
State Street SPDR S&P Biotech ETF made up 0.49% of Pinz Capital Management's portfolio in Q3 2022, its #62 holding.
Pinz Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and has held it in 4 quarters since.
Pinz Capital Management's State Street SPDR S&P Biotech ETF position peaked at $806K in Q4 2021.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Pinz Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.